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Idiopathicpulmonaryﬁbrosis(IPF)isadiseaseofunknownetiologywithconsiderablemorbidityandmortality.Cigarettesmoking
is one of the most recognized risk factors for development of IPF. Furthermore, recent work suggests that smoking may have a
detrimental eﬀect on survival of patients with IPF. The mechanism by which smoking may contribute to the pathogenesis of IPF is
largely unknown. However, accumulating evidence suggests that increased oxidative stress might promote disease progression in
IPF patients who are current and former smokers. In this review, potential mechanisms by which cigarette smoking aﬀects IPF, the
eﬀects of cigarette smoking on accelerated loss of lung function in patients with IPF, key genetic studies evaluating the potential
candidate genes and gene-environment (smoking) interaction, diagnosis, and treatment with emphasis on recently closed and
ongoing clinical trials are presented.
1.Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is deﬁned as a speciﬁc
form of chronic, progressive ﬁbrosing interstitial pneumonia
of unknown cause, occurring primarily in older adults,
limited to the lungs, and associated with the histopathologic
and/or radiologic pattern of usual interstitial pneumonia
(UIP) [1]. Current estimates of IPF prevalence and annual
incidence in the United States range from 14 to 42.7 per
100 000 and 6.8–16.3 per 100 000, respectively [2]. There
is a high unmet need for novel therapies as conventional
therapy has limited eﬃcacy or an unfavorable safety proﬁle
and there are no US Food and Drug Administration- (FDA-
) approved therapies for IPF treatment. In a recent meta-
analysis of observational studies examining environmental
and occupational risk factors for IPF, signiﬁcantly increased
risk for IPF was associated with cigarette smoking and
exposure [3]. Several environmental exposures also have
been associated with increased risk for IPF. Occupational
factors, primarily metal and wood dust exposure, adjusted
for age and smoking, have been found to be signiﬁcantly
associated with IPF [4, 5]. Among these risk factors, cigarette
smoking seems to be the most strongly associated risk factor
in both sporadic IPF and familial pulmonary ﬁbrosis [3, 6].
The prevalence of tobacco use in IPF ranges from 41% to
83%, depending on the case deﬁnition used in the studies
[7, 8]. Current or former smokers have consistently been
overrepresented in IPF [9–13]. In one case-control study,
smoking was identiﬁed as a potential risk factor for the
development of IPF (odds ratio [OR] = 1.6) [14]. The overall
OR for smoking as a risk factor for IPF was 1.58. There is
an independent strong association between smoking and the
development of familial interstitial pneumonia of various
subtypes including UIP (OR, 3.6; 95% conﬁdence interval,
1.3–9.8) [6]. Recent work suggests that smoking may have a
detrimental eﬀect on survival of patients with IPF. Antoniou
andcolleaguesreport thatlife-longnonsmokers haveabetter
outcome than former smokers and the combined group of
current and former smokers in IPF in a study of 249 patients,
186hadasmokinghistory,althoughpathogeneticdiﬀerences
have yet to be elucidated [15]. Interestingly, in a large study
of IPF, King Jr et al. demonstrated that current smokers
have a much longer survival than former smokers, an eﬀect
that remained statistically signiﬁcant after adjustment for
functional impairment, age, and chest radiographic severity
of disease [16]. It is, however, unclear whether ongoing
smoking is genuinely protective against disease progres-
sion as a “healthy smoker eﬀect” (i.e., smoking cessation2 Pulmonary Medicine
prompted by more rapidly progressive disease) cannot be
excluded [17, 18].
The mechanism by which smoking may contribute to the
pathogenesis of IPF is unknown despite studies suggesting
a strong association between the development of IPF and
cigarette smoking. Because IPF is recognized as a disease of
aging, it has been speculated that smoking may contribute
to the development of interstitial lung disease in an age-
dependent manner [19]. Also, there is a suggestion that
increased oxidative stress in current and former smokers
might promote disease progression [20]. Examination of
high-resolution computed-tomography (HRCT) scan im-
ages has revealed that some patients with IPF, primarily male
smokers, may display the combination of emphysematous
lesions and pulmonary ﬁbrosis, which has been called
combined emphysema and pulmonary ﬁbrosis [21, 22].
These patients develop severe pulmonary hypertension and
present decreased survival rate compared with patients with
IPF alone. Smoking is a deﬁnite risk factor for developing
chronic obstructive pulmonary disease (COPD). Some of
the underlying ﬁbrotic remodeling changes that occur in
lungs of COPD patients exhibit IPF-like pathologies, with
remodeling being evident in the interstitial regions [23],
but no underlying interstitial lung disease [24, 25]. It is
unknown whether this increase is related to the abnormal
pathways upregulated in the disease or, as seems to be the
case in IPF combined with emphysema, this relationship
is not causal but directly associated to smoking [26]. A
search for the potential mechanisms by which cigarette
smoking aﬀects patients with IPF may provide insights on
the development of novel therapeutic targeted agents against
smoking-induced progression of IPF.
2. Pathogenesis of IPF
At the cellular level, IPF is characterized by ﬁbroblast prolif-
eration and activation, resulting in pronounced extracellular
matrix (ECM) deposition [27]. Histologically, ﬁbrotic areas
of the IPF lung are adjacent to areas of mononuclear
cell inﬁltration and areas of normal parenchyma. There is
considerable epithelial cell apoptosis as well as the abnormal
presence of myoﬁbroblasts in the lung parenchyma [28].
Collectively, these cell phenotypic alterations contribute
towards the reduced eﬃciency of gas exchange due to excess
ECM deposition, whilst enhancing the contractility of the
lung tissue and thus reduced lung tissue compliance.
Fibroblasts are stromal cells that support tissue home-
ostasis through the generation of ECM during normal
w o u n dh e a l i n g ,a sw e l la sd i ﬀerentiating into alpha-smooth
muscle actin-positive myoﬁbroblasts. In addition to being
highly synthetic, myoﬁbroblasts are proposed to contract
wound edges together, thus sealing oﬀ injured tissue and
preventing damage or subsequent infection [29]. During
normal wound healing, myoﬁbroblasts apoptose and scar
tissue resolves, in part via enzymatic matrix metallopro-
teinase (MMP) generation [30]. However, in the case of
IPF, myoﬁbroblasts persist in the lung, generating even more
ECM and further contributing to the underlying scar tissue
[31]. These cells also have a heightened ﬁbrotic baseline,
producing greater levels of ECM and proﬁbrotic mediators,
as well as expressing greater levels of proﬁbrotic receptors
such as transforming growth factor- (TGF-) α receptors and
interleukin- (IL-) 13 receptors [32].
Idiopathic pulmonary ﬁbrosis ﬁbroblasts have a lower
threshold for activation and thus can have an augmented
proﬁbrotic response to mediators found in the IPF lung [32].
Fibroblasts are activated by a number of processes ranging
from physical stretch, to alterations in underlying ECM and
directly by soluble mediators including growth factors and
reactive oxygen and nitrogen species (RONS) [33]. However,
ﬁbroblasts can also be activated by apoptotic debris found at
sites of injury and inﬂammation to generate excess ECM and
proﬁbrotic mediators and undergo apoptosis [34].
As well as being highly activated, there is an increase
in ﬁbroblast number in the lungs of IPF patients, which in
part may be due to a relative resistance to apoptosis [35].
However, the sources of ﬁbroblasts during IPF appear to
be altered when compared to healthy nonﬁbrotic control
patients. For example, one process by which ﬁbroblasts have
recently been described to arise from is the epithelium.
Epithelial abnormalities have been described histologically
in IPF, with areas of apoptosis and denuded epithelium
prevalent in the ﬁbrotic lung [36].
Epithelial-to-mesenchymal transition (EMT) is a pro-
cess that occurs normally during early fetal development
where a seamless plasticity exists between epithelial and
mesenchymal cells [37]. During EMT, epithelial markers
including tight junction proteins are downregulated and
a concomitant upregulation of mesenchymal markers is
observed, with the cells becoming more motile [38, 39]. This
phenomenon is well accepted in cancer as a key mechanism
that supports tumor progression and metastases [40], and in
contrast to developmental EMT, tumorigenic EMT is poorly
regulated [41]. In chronic lung diseases, the dual expression
of epithelial and mesenchymal markers in the same cells has
led investigators to postulate EMT as a mechanism resulting
in more ECM-generating cells in the lung [42, 43]. The
diﬀerentiation of airway epithelial cells has been previously
described, for example, type I pneumocytes transitioning
into goblet cells, which may in part explain the increase
in mucus production in asthma [44–47]. However, the
switching of an epithelial cell into a phenotype that moves
beyond the original cell’s embryonic lineage, that is, into
mesenchymal cells, has only recently been hypothesized as
a driving factor in ﬁbrosis [39, 48, 49].
Epithelial cells exposed to the prototypic proﬁbrotic
growth factor TGF-α 1, alone or in combination with other
growth factors such as epidermal growth factor, begin the
process of EMT by increasing the expression of MMPs
[40, 50]. These enzymes will promote basement membrane
degradation and cell detachment, allowing for enhanced cell
motility. The cells also undergo cytoskeletal changes, as well
as altered expression of surface molecules, which allow for
the migration and transition of these cells to a mesenchymal
phenotype [50, 51]. The idea of EMT promoting the ﬁbrosisPulmonary Medicine 3
observed in IPF is rapidly beginning to evolve [47]. Several
recent studies have also shown that EMT occurs in lung
epithelial cells both in vitro and in vivo, supporting the
concept of EMT contributing to the ﬁbrosis observed in IPF
[47, 52, 53].
Another potential source of lung ﬁbroblasts is the bone
marrow. Fibroblasts, traditionally thought to arise from
proliferation of resident stromal cells, have been shown to
derive from CD45+ collagen-I-producing cells, commonly
referred to as “ﬁbrocytes” [54–56]. During in vitro culture,
circulating CD45+ collagen I+ cells downregulate CD45
and become more adherent [57]. Moreover, in experimental
models of lung ﬁbrosis, tracing circulation-derived collagen-
I-producing cells conﬁrmed this downregulation of the
hematopoietic marker [54]. Fibrocytes have been observed
at sites of active ﬁbrosis and increased circulating numbers
correlate with mortality in IPF [58]. They are induced by
proﬁbrotic mediators such as TGFβ1 and Th2 cytokines
[59]; and express a variety of markers including leukocyte
markers (CD45, CD34), mesenchymal markers (collagen
I, ﬁbronectin), and chemokine receptors (CCR3, CCR5,
CCR7, and CXCR4) [60]. Human and mouse studies have
demonstrated that ﬁbrocytes from peripheral blood migrate
toskinwoundchambers[60,61];andbronchialmucosaafter
antigen challenge [62]. Furthermore, these cells have been
reported in disease states with ﬁbrotic pathologies including
hypertrophic scars, asthma, and IPF [62–65]. Fibrocytes are
pleiotropic and may contribute to ﬁbrogenesis by directly
producing collagen, as well as inﬂammatory cytokines,
hematopoietic growth factors, and chemokines [32, 54, 57,
64, 65]. While it was originally thought that ﬁbrocytes
promote ﬁbrosis through production of ECM components,
it is becoming increasingly hypothesized that their primary
roleintissueremodelingmaybethroughsecretionofsoluble
factors [56].
The acute and initial recognition of these foreign medi-
ators initiates a host defense response, resulting in clearance
of the noxious agents being mediated by the innate immune
system in the lung [66]. One of the ﬁrst immune cell types
in the lung to encounter foreign pathogens is the alveolar
m a c r o p h a g e .M a c r o p h a g e s ,a sw e l la sﬁ b r o c y t e s ,d e r i v e
from monocytes. Following classical activation, as occurs
during pathogen recognition and ultimate phagocytosis and
clearance, the resultant monocyte-derived cell is the M1
macrophage or “classically activated macrophage [66].” In
the ﬁbrotic lung, the predominant macrophage phenotype
is the “alternatively activated macrophage,” or the M2 ma-
crophage [67, 68]. Alveolar macrophages are known to
removeapoptoticandnecroticdebris.Inhealthytissue,these
cells phagocytose debris and pathogens in a nonphlogistic
mechanism,inthatdownstreaminﬂammationislimitedand
the inﬂammatory process is attenuated [69]. In contrast, M2
macrophages are defective at intracellular killing following
phagocytosis and dampen the inﬂammatory response [66].
These macrophages are capable of synthesizing proﬁbrotic
mediators, which supports their role in wound healing, but
this cell type is ineﬃcient at supporting host defense [66].
The presence of M2-skewed macrophages may explain why
patients with IPF are susceptible to exacerbation of disease.
M2 macrophages express elevated levels of scavenger
receptors such as macrophage scavenger receptor and man-
nose receptor C (MRC/CD206) [66, 70]. Assessing circu-
lating primary cells from IPF patients, we have previously
described an elevation of CD163+ and CD14+ cells, and
M2-associated soluble mediators in the circulation, which
was more pronounced in progressive IPF patients. This was
suggestive of an overall elevated M2 background in these
patients [71]. We have also shown that peripheral blood
monocytes from patients with scleroderma-related lung
disease display a proﬁbrotic phenotype, characterized by
increased CD163 expression and CCL18 expression [72].
Studies of bleomycin-induced ﬁbrosis have assessed
e i t h e rM 2m a c r o p h a g eo rﬁ b r o c y t en u m b e r[ 71, 73]. It is
increasingly recognized that there is some overlap between
thesecellsubsetsintermsofbothfunctionandmarkers[73].
However, although both ﬁbrocytes and M2 macrophages
can be derived from monocytes, they are not completely
redundantinfunction.Recently,usingalung-speciﬁcTGFβ1
overexpression model of lung ﬁbrosis, we have determined
that depletion of lung monocyte/macrophages using liposo-
mal clodronate reduced collagen accumulation, but this had
no eﬀect on the TGFβ-induced ﬁbrocyte recruitment [74].
3. Mechanismsby which Smoking Contributes
to the Pathogenesis of IPF
Cigarette smoke contains particulate matter as well as nu-
merous chemicals including highly toxic RONS [75, 76].
These have been hypothesized to exacerbate lung pathology
in a number of ways, including altering both the ox-
idant/antioxidant balance and the protease/antiprotease bal-
ance in the lung; as well as promoting cellular apoptosis
and necrosis and generating DNA and lipid intermediates,
thus exacerbating inﬂammation [77–86]. Animal models
of cigarette-smoke-induced lung injury are often used for
COPD research [84, 87]. Mice challenged with cigarette
smoke via passive inhalation exhibit pulmonary neutrophilia
after acute (less than 5 days) or chronic (multiple weeks)
exposure schedules [87]. The pathology observed in the
acute models resolve spontaneously and these models are
used to study the inﬂammation associated with COPD. In
contrast, the chronic models generally demonstrate markers
of lung destruction, alveolar collapse, and aberrant protease
imbalance. There is also increased collagen deposition in
chronic smoke models, however, unlike the gold-standard
IPF model, the intratracheal bleomycin, the extent of
parenchymal remodelling, ﬁbroblastic foci, and ﬁbroprolif-
eration is limited. Interestingly, cigarette smoke exposure has
been demonstrated to increase susceptibility of bleomycin-
induced lung ﬁbrosis [88].
In vitro studies assessing the eﬀects of cigarette smoke
have demonstrated that ﬁbroblasts can produce an emphy-
sematous response and increase MMP production [89–92].
The epithelium, which is one of the ﬁrst cells exposed to the
noxious chemicals and particles during smoking, responds
in a multitude of ways to these stimuli in vitro [93]. These
can range from enhanced proinﬂammatory mediator pro-
duction, to undergoing apoptosis and necrosis, dependent4 Pulmonary Medicine
on the degree of stimulation. The eﬀect of cigarette smoke
on EMT has not been determined. Moreover, correlating the
extent of epithelial damage in multiple regions of the lungs
of any individual patient with smoking history may elucidate
any direct relationship.
Cigarettesmokealsoaltersthewayinwhichmacrophages
recognize foreign particles and pathogens [94]. The debris
that is generated from apoptotic and necrotic cells has
recently been shown to enhance inﬂammation and down-
stream remodeling, through various receptors including
toll-like receptors and other pattern recognition receptors
including formyl peptide receptors and C-type lectins, which
are commonly expressed on alveolar macrophages [95–98].
It still remains to be conﬁrmed whether it is the direct
recognition and phagocytosis of particulate matter that
results in apoptosis, or the cigarette-smoke-derived RONS
that enhances cellular activation and death. Cigarette smoke
induces an M2-type macrophage phenotype and this was
paralleled during an in vivo cigarette smoke model in mice
[99]. Therefore, understanding whether cigarette smoke has
any direct eﬀect on promoting M2 macrophage expansion
may help identify novel pathogenic pathways for smoking at
promoting IPF.
Due to the plethora of mediators capable of activating
cells, the combination of mediators may have a synergistic
eﬀect in the lungs of patients with IPF. Recent evidence sug-
gests that individuals respond diﬀerently to cigarette smoke
compounds in part through an altered unfolded protein
response, resulting in either susceptibility or resistance to the
same stimuli [100]. As has been discussed, cigarette smoke
contains numerous stimuli and can thus have a multitude
of downstream pathogenic responses on the variety of cells
found in the IPF lung. Therefore, understanding the under-
lying environment and ﬁbrotic milieu the cigarette smoke
encounters may be central to the extent of the resultant
ﬁbrosis and may explain why not all smokers develop IPF or
any of the more classically smoking-associated lung diseases
including COPD and cancer.
4.GeneticFactors
Although the etiology is unknown, a signiﬁcant percentage
of patients with IPF have a familial form of the disease,
suggesting genetics might play a role [6, 101]. Based on
a genome-wide scan in Finnish families, Hodgson et al.
reported a candidate gene for susceptibility for IPF named
ELMOD2 (engulfment and motility domain containing 2),
a gene of unknown biological function located on chromo-
some 4q31 [102, 103]. ELMOD2 belongs to the group of
six human proteins containing the ELMO domain, which
is essential for cellular processes, such as phagocytosis of
apoptotic cells and cell migration [104–106]. Pulkkinen et
al. later discovered that the major downstream pathways of
ELMOD2 are involved in induction of type I and type III
interferon mRNA expression, suggesting that ELMOD2 has
a role in antiviral responses [107].
Genetic variants within the human telomerase reverse
transcriptase (hTERT) or human telomerase RNA compo-
nents of the telomerase gene are associated with familial
pulmonary ﬁbrosis and are present in some sporadic IPF
cases. Heterozygous loss-of-function mutations in TERT
have been found in up to 15% of kindreds with familial
pulmonary ﬁbrosis [108, 109] and in 1% to 3% of sporadic
cases [110, 111]. Recently, Diaz de Leon et al. examined
the telomere lengths and pulmonary ﬁbrosis phenotype seen
in multiple kindreds with heterozygous TERT mutations
and reported that TERT mutation carriers have reduced life
expectancy [112]. Furthermore, the TERT mutation carriers
have higher fractional tissue volume, which is inversely
correlated with forced vital capacity and diﬀusing capacity of
the lung for carbon monoxide, and are especially apparent
in carriers that smoked, suggesting that smoking is an
additional risk factor for loss of lung function in patients
with IPF.
A number of candidate genes have been evaluated in
search for genetic factors in sporadic cases of IPF. Among
others, the following polymorphisms of genes are reported
to be associated with increased frequencies in patients with
sporadic IPF: genes encoding for cytokines, such as IL-1
a, tumor necrosis factor-α,l y m p h o t o x i nα,I L - 4 ,I L - 6 ,I L -
8, IL-10, IL-12, and TGF-ß1 [113–123], α 1 antitrypsin
and angiotensin-converting enzymes [116, 124], proﬁbrotic
molecules (TGF-β1), coagulation pathway genes (plasmino-
gen activator inhibitors-1 and -2 and surfactant proteins-
Aa n d- B )[ 125], and MMP-1 [126]p o l y m o r p h i s m s ,h a v e
been reported to have increased frequencies in patients with
sporadicIPF.Unfortunately,however,theseﬁndingshavenot
been reproduced in subsequent studies.
R131H (rs1801274) polymorphism of the immunoglob-
ulin G receptor FcγRIIa determines receptor aﬃnity for
immunoglobulin G subclasses and is associated with several
chronicinﬂammatorydiseases.Inacase-controlstudy,Bour-
nazos et al. compared the distribution of FcγRIIa R131H
genotypes in 142 patients with IPF and in 218 controls
usingallele-speciﬁcpolymerasechainreactionampliﬁcation.
These ﬁndings support an association between the FcγRIIa
R131H polymorphism and IPF severity and progression,
suggesting the involvement of immunological mechanisms
in IPF pathogenesis [127].
Xaubet et al. demonstrated that the carriage of double
homozygote (GG/CC) at the single nucleotide polymor-
phism loci of COX2.3050 and COX2.8473 polymorphisms
did not increase disease progression but may increase the
susceptibility to IPF by approximately 1.4 fold at age 30
and by a smaller fold greater than 1 up to age 66 years
[128]. These ﬁndings may help to improve understanding of
IPF pathogenesis and may lead to the development of new
therapeutic strategies.
In the case-control study described above, Bournazos
et al. also compared the distribution of FcγRIIIb NA1/2
polymorphisms using allele-speciﬁc polymerase chain reac-
tion ampliﬁcation and demonstrated that FcγRIIIb NA1/2
polymorphismsareassociatedwithIPFdiseasesusceptibility.
These results support a role for immunological mechanisms
contributing to IPF pathogenesis [129].
Currently, the ATS/ERS/JRS/ALAT (American Thoracic
Society, European Respiratory Society, Japanese Respira-
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committee does not recommend genetic testing in patients
with either familial or sporadic IPF, as part of clinical
evaluation because more functional studies that conﬁrm
their signiﬁcance and studies investigating other mutations,
associations,andgene-environmentrelationshipsareneeded
[1].
Cigarette smoking has been associated with IPF in case-
control studies with patients of diﬀerent ethnic backgrounds
and with patients with familial pulmonary ﬁbrosis, indi-
cating that smoking may confer increased risk for IPF [3,
6]. Checa et al. [126] demonstrated that a putative gene-
environment interaction exists between the single nucleotide
genetic variant (G/T) at −755 of the MMP-1 promoter
and the presence of IPF in smokers. −755 of the MMP-
1 promoter creates a potential binding site for transcrip-
tion factors of the activation protein-1 (AP-1) family and
thus may inﬂuence the transcriptional responsiveness of
the MMP-1 promoter. They found that the TT genotype
is increased in cigarette-smoking IPF patients, suggesting
that the TT genotype may modulate an interaction with
smoking, resulting in an increased susceptibility to develop
the disease—a potential gene—environment interaction
between the polymorphism and smoking in IPF. Barnes et
al. demonstrated that cigarette smoke induces acetylation
of histone H4 and decreases histone deacetylase- (HDAC-)
2 activity and expression. Coward et al. [130, 131] also
reported that decreased histone acetylation and methyla-
tion is responsible for the repression of the antiﬁbrotic
cyclooxygenase-2 gene and the potent angiostatic chemokine
gammainterferon-(IFN-γ-)inducibleproteinof10kDa(IP-
10) in lung ﬁbroblasts from patients with IPF. These ﬁnd-
ings suggest that epigenetic dysregulation involving histone
deacetylation and hypermethylation by cigarette smoking
may promote ﬁbrotic changes in the lung disease of IPF
patients.
5.Diagnosis
Diagnosis of an IPF can be achieved with certainty only
after the pulmonologist, radiologist, and pathologist have
reviewed all of the clinical, radiologic, and pathologic
data. The diagnostic criteria for IPF are presented in the
ATS/ERS Statement [1]. In the appropriate clinical setting,
the presence of a UIP pattern on HRCT is suﬃcient for
the diagnosis of IPF. Thus, the major and minor criteria for
the clinical (i.e., nonpathologic) diagnosis of IPF have been
eliminated in this new ATS/ERS Statement [1].
Idiopathic pulmonary ﬁbrosis is an idiopathic inter-
stitial pneumonia characterized by UIP histopathology. A
conﬁdent histopathologic diagnosis of UIP either through
a surgical lung biopsy or a characteristic HRCT scan of
the chest must be correlated with the clinical ﬁndings. The
histopathologic criterion is a heterogeneous appearance of
areas of ﬁbrosis with scarring and honeycomb change and
areas of less aﬀected or normal parenchyma [1]. These chan-
ges predominantly aﬀect the subpleural and paraseptal pa-
renchyma. Inﬂammation is usually mild and consists of
a patchy interstitial inﬁltrate of lymphocytes and plasma
cells. The ﬁbrotic zones are composed of dense collagen,
proliferating ﬁbroblasts and myoﬁbroblasts, as well as areas
of honeycomb change. In the absence of histologic features
diagnostic of an alternative condition such as hypersensitiv-
ity pneumonitis or autoimmune diseases, such biopsies may
be consistent with the diagnosis of IPF.
The typical chest radiograph in IPF shows bilateral
basal and peripheral reticular opacities. Progressive ﬁbrosis
leads to a reduction in lung volumes and honeycombing,
which tends to become less frequent towards the upper
lung subpleural zones. In IPF, signs of pulmonary ﬁbrosis
include traction bronchiectasis and architectural distortion
suchasﬁssuredisplacement,whichcanbedetectedbyHRCT
[132, 133]. High-resolution computed tomography has been
shown to be a highly accurate tool for diagnosis of UIP, with
a positive predictive value of 95% to 100% [134]. Therefore,
the diagnosis of IPF can be made on the basis of HRCT and
clinical evaluation without the need for surgical biopsy.
However, some cases of UIP are diﬃcult to diﬀerentiate
from ﬁbrotic nonspeciﬁc interstitial pneumonia, which may
exhibit honeycombing. The most useful ﬁnding when dif-
ferentiating between nonspeciﬁc interstitial pneumonia and
UIP at HRCT is the greater extent of honeycombing in
cases of UIP [135]. The HRCT diﬀerential diagnosis of
IPF includes pulmonary ﬁbrosis related to connective tissue
disease and asbestosis, hypersensitivity pneumonitis, and
drug toxicity.
Increasing research evidence indicates that smoking
may also result in interstitial lung abnormalities on HRCT
[136, 137]. Smokers who develop IPF often have respira-
tory bronchiolitis-interstitial lung disease and desquamative
interstitial pneumonitis changes at HRCT and histopatho-
logic analysis, and patients with desquamative interstitial
pneumonitis may develop an HRCT pattern of ﬁbrotic
nonspeciﬁc interstitial pneumonitis over time [138]. A
combination of smoking-related-interstitial lung disease-
related HRCT ﬁndings, such as ground-glass opacities,
cysts, micronodules, septal thickening, and honeycombing,
can be seen in the same patient, confounding radiologic
classiﬁcation into a discrete smoking-related entity.
Clinical features of IPF include gradually progressing
dyspnea, chronic cough, and bibasilar inspiratory crackles
[6]. Digital clubbing is seen in approximately two thirds of
patients. Pulmonary function tests usually demonstrate a
restrictive defect with reduced lung volumes and diﬀusing
capacity.Idiopathicpulmonaryﬁbrosisshouldbeconsidered
in all adult patients with unexplained chronic exertional
dyspnea and commonly presents with cough, bibasilar inspi-
ratory crackles, and ﬁnger clubbing [139]. Active smoking
in patients with IPF has been shown to be associated with
higher values of residual volume and functional residual
c a p a c i t y ,a sw e l la sw i t hag r e a t e rd e c r e a s ei nd i ﬀusing
capacity of the lung for carbon monoxide [140]. More
recently, Washko et al. [23] demonstrated that interstitial
lung abnormalities, which were present on about 1 of every
12 HRCT scans, were associated with reduced total lung
capacityandalesseramountofemphysemainsmokersusing
the COPD Gene Study cohorts [137, 141].6 Pulmonary Medicine
Table 1: Closed clinical trials in pulmonary ﬁbrosis.
Title: description Phase Primary outcomes
measure Trial duration ClinicalTrials.gov
ID
Minocycline Therapy for Lung Scarring in Pts with
IPF—A Pilot Study: evaluates the safety and eﬃcacy of
minocycline
3S a f e t y ; e ﬃcacy 9/13/2005 to (date n/a) NCT00203697
Interferon-Alpha Treatment of Chronic Cough in
COPD and IPF: evaluates the eﬀect lozenges containing
interferon-alpha have on coughing
2 Frequency/severity of
cough 6/30/2008 to 3/31/2012 NCT00690885
Eﬃcacy and Safety of Oral Bosentan in Pts with IPF:
this double-blind, multicenter trial investigated the
possible use of bosentan in pts with IPF
2/3 Change in 6MWD 8/31/2003 to 5/31/2010 NCT00071461
Zileuton for the Treatment of IPF: an open-label trial of
zileuton compared to azathioprine/prednisone for pts
with IPF. Pts underwent a detailed assessment at
baseline, followed by 3 mos of posttreatment
monitoring for changes in symptoms and physiology
2
Change in LTB4 levels in
bronchoalveolar lavage
ﬂuid
1/31/2001 to (date n/a) NCT00262405
Open-Label, Extension Study in Patients with IPF Who
Completed Protocol AC-052-321/BUILD 3: an
open-label, extension study
3 Long-term safety and
tolerability of bosentan 3/31/2008 to 7/31/2010 NCT00631475
Bosentan Use in ILD: BUILD 3 was a prospective,
multicenter, randomized, double-blind, parallel-group,
placebo-controlled, event-driven, group sequential,
superiority study
3
Time to occurrence of
disease worsening or
death up to end of study
11/30/2006 to
7/31/2010 NCT00391443
Pirfenidone for the Treatment of Pts with PF/IPF:
assessed the long-term safety and eﬃcacy of oral
pirfenidone in doses of up to 40mg/kg/day
2
AEs, clinical laboratory
tests, directed physical
exams
8/31/2003 to 1/31/2011 NCT00080223
Open-Label Study of the Long Term Safety of
Pirfenidone in Pts with IPF: an open-label, multicenter,
extension study for pts who completed the CAPACITY
trials (PIPF-004 and PIPF-006)
3 Obtain safety data 8/31/2008 to 7/31/2012 NCT00662038
Macitentan Use in an IPF Clinical Study: the
AC-055B201/MUSIC study compared one dose of
macitentan versus placebo in pts with IPF
2 FVC changes 5/31/2009 to 6/30/2011 NCT00903331
Anticoagulant Eﬀectiveness in IPF: tested the
eﬀectiveness of warfarin in pts with IPF 3
Time to death,
nonbleeding/nonelective
hospitalization, or >10%
drop in FVC
10/31/2009 to
12/31/2011 NCT00957242
Roll Over Study from 1199.30 BIBF-1120 in IPF: this
open-label, non-randomized uncontrolled design trial
oﬀers continuation of BIBF-1120 treatment for pts with
IPF who have completed a prior clinical trial (1199.30)
with that drug. Primary objective is to establish a
long-term tolerability and safety proﬁle. Secondary
objectives are eﬀects of long-term treatment on
survival, safety, and eﬃcacy
2 FVC decline (time
frame: 3 years average) 6/30/2010 to 6/30/2015 NCT01170065
IPF: idiopathic pulmonary ﬁbrosis. n/a: not available. COPD: chronic obstructive pulmonary disease. 6MWD: six-minute walking distance. LTB4: leukotriene
B4. ILD: interstitial lung disease. BUILD: bosentan use in interstitial lung disease. PF: pulmonary ﬁbrosis. AE: adverse event. MUSIC: macitentan use in an
idiopathic pulmonary ﬁbrosis clinical study. FVC: forced vital capacity.
6.Treatment andPrognosis
The treatment of IPF remains a great challenge as there is
no eﬀective therapeutic option. The clinical course is gradual
deterioration with a median survival of 2.5 to 3.5 years
[142]. Treatment remains largely supportive; prednisone
monotherapy or prednisone combined with azathioprine or
cyclophosphamide, methotrexate, colchicine, penicillamine,
orcyclosporinehavebeentriedbuthavefailedorarenotwell
tolerated by the patient. Supportive care includes supple-
mental oxygen, vaccination against inﬂuenza and pneumo-
coccus,pulmonary rehabilitation, treatmentwith regularuse
of immunosuppressant/antioxidant therapy, referral for lung
transplant evaluation (when appropriate), and identiﬁcation
and treatment of comorbidities including gastroesophageal
reﬂux disease, sleep disordered breathing, coronary disease,
and pulmonary hypertension [143].Pulmonary Medicine 7
Table 2: Ongoing clinical trials in pulmonary ﬁbrosis.
Title: description Phase Primary outcomes
measure Trial duration ClinicalTrials.gov
ID
Bosentan in PH in ILD Treatment Study: aims to determine the
ability of bosentan to reduce PH in patients with scarring (ﬁbrosing)
lung disease
4 Fall in PVR of 20% over
16 wks
4/30/2008 to
8/31/2010 NCT00637065
Treprostinil Therapy for Pts with ILD and Severe PAH: the hypothesis
is that IV or SC treprostinil can improve 6MWD, hemodynamics and
QOL in pts with ILD and severe secondary PAH
36 M W D 1/31/2008 to
2/28/2009 NCT00705133
PAH Secondary to IPF and Treatment with Sildenaﬁl: evaluates
whether sildenaﬁl improves morbidity and mortality in the peri-lung
transplant setting in both IPF cohorts with either resting or exercise
PAH
46 M W D 2/28/2007 to
2/31/2009 NCT00625079
Pilot Study of a Multi-Drug Regimen for Severe PF in HPS: evaluates
if pravastatin, losartan, zileuton, N-acetylcysteine, and erythromycin
used together can slow the course of PF in pts with HPS
1/2 Survival 4/30/2007 to
(date n/a) NCT00467831
A Study to Evaluate the Safety and Eﬀectiveness of CNTO-888
Administered IV in Subjects with IPF: evaluates safety and eﬃcacy of
CNTO-888
2 Pulmonary function and
safety
12/31/2008 to
6/30/2012 NCT00786201
Losartan in Treating Pts with IPF: evaluates the safety and eﬃcacy of
losartan n/a FVC 3/31/2009 to
(date n/a) NCT00786201
Losartan in Treating PF Caused by Radiation Therapy in Pts with
Stage I, II, or III NSCLC: evaluates the eﬃcacy of losartan in this pt
population
n/a
Change in carbon
monoxide diﬀusing
capacity
5/31/2009 to
(date n/a) NCT00880386
Trial of Iloprost in PH Secondary to PF: evaluates safety and eﬃcacy
of iloprost 3 Safety; pulmonary
arterial pressure; 6MWT
3/31/2007 to
8/31/2007 NCT00439543
Targeting Vascular Reactivity in IPF: evaluates if combination therapy
with N-acetylcysteine, sildenaﬁl, and losartan can improve function
and exercise tolerance in pts with IPF
2/3 A 6MWT; QOL score 9/30/2009 to
7/31/2013 NCT00981747
Pomalidomide for Cough in Pts With IPF: evaluates the safety and
eﬃcacy of pomalidomide over a 12-week duration in the treatment of
chronic cough in pts with IPF
2 Cough-related QOL 7/31/2010 to
7/31/2013 NCT01135199
Trial of IW-001 in Pts with IPF: an open-label, multicenter study
designed to explore the biological and clinical eﬀects of IW-001 1 Safety and tolerability 9/30/2010 to
9/30/2011 NCT01199887
A Study to Characterize the Safety, PK and Biological Activity of
CC-930 in IPF: evaluates the safety and PK proﬁle of CC-930 2S a f e t y a n d P K 1/31/2011 to
1/30/2013 NCT01203943
Safety and PK Study with AB-0024 in Pts with IPF: this
dose-escalation study evaluates the safety, tolerability, PKs, and
pharmacodynamics of AB-0024
1S a f e t y a n d P K 12/31/2010
to/31/2012 NCT01242189
A Study of the Safety, Tolerability, PKs, and Pharmacodynamics of IV
PRM-151 in Pts with IPF: this study includes multiple doses of IV
PRM-151
1b Safety and tolerability 1/31/2011 to
8/31/2011 NCT01254409
Safety, Tolerability, and Eﬃcacy Study of IPF: evaluates the safety and
tolerability of FG-3019 in pts with IPF and the eﬃcacy of FG-3019 for
attenuating ﬁbrosis in these pts
2a Safety and tolerability 12/31/2010 to
12/31/2012 NCT01262001
Safety and Eﬃcacy of QAX-576 in Pts with Progressive IPF: designed
to evaluate the safety, tolerability, PKs and eﬃcacy of QAX-576 in pts
with rapidly progressive IPF
2 Safety, tolerability, and
eﬀect on lung function
12/31/2010 to
(date n/a) NCT01266135
Combined PEX, Rituximab (a chimeric MAb against the protein
CD20) and Steroids in Acute IPF Exacerbations: an open-label trial to
compare combined plasma exchange, rituximab, and conventional
corticosteroid administration on the outcomes of hospitalized pts
1/2 Feasibility and safety 3/31/2011 to
(date n/a) NCT01266317
Safety and Eﬃcacy of BIBF-1120 at High-Dose in IPF Pts:. a
prospective, randomized trial that compares BIBF-1120 with placebo 3 Annual rate of decline in
FVC
4/30/2011 to
1/31/2014 NCT01335464
PH: pulmonary hypertension. ILD: interstitial lung disease. PVR: pulmonary vascular resistance. IPF: idiopathic pulmonary ﬁbrosis. PAH: pulmonary arterial
hypertension. 6MWD: six-minute walk distance. QOL: quality of life. PF: pulmonary ﬁbrosis. n/a: not available. HPS: Hermansky-Pudlak syndrome. FVC:
forced vital capacity. NSCLC: non-small cell lung cancer. 6MWT: 6-minute walk test. PK: pharmacokinetic. PEX: plasma exchange. MAb: monoclonal
antibody.8 Pulmonary Medicine
Pirfenidone is an oral antiﬁbrotic, anti-inﬂammatory,
and antioxidant agent that inhibits TGF-β in vitro [144]. It
was approved for use in the management of IPF in Japan
in 2008 [145] based on a Japanese phase 3 study involving
267 patients who had been randomly assigned to receive
placebo, high-dose (1,800mg daily), or low-dose (1,200mg
daily) pirfenidone over 52 weeks. The primary endpoint of
change in lung vital capacity showed signiﬁcant preservation
of this parameter between the placebo group and the high-
dose group (P = .0416). Pirfenidone was also studied
in two additional multinational, randomized, double-blind,
placebo-controlled phase 3 trials (CAPACITY 1 and CAPAC-
ITY 2) conducted in IPF patients. The CAPACITY 1 trial
enrolled344patientsandinvolvedadailydoseof2,403mgof
pirfenidone versus placebo. The CAPACITY 2 trial enrolled
435 patients who were randomly assigned 2:2:1, respec-
tively, to pirfenidone 2,403mg daily, placebo, or pirfenidone
1,197mgdailyovera72-weektreatmentperiod.Theprimary
endpoint of change in forced vital was met in CAPACITY
2( P = .001) but not in CAPACITY 1 [146]. Largely based
on these data, the European Commission granted marketing
authorization for pirfenidone in 2011. In 2010, however,
the FDA declined to approve the use of pirfenidone for the
treatment of IPF, requesting additional clinical trials.
Given the high morbidity and mortality associated with
IPF and the absence of FDA-approved, eﬀective therapies,
a wide array of therapeutic approaches are under active
clinical investigation. Some key clinical studies evaluating
the potential usefulness of the newer agents (e.g., IFN-
gamma-1b, pirfenidone, N-acetylcysteine, warfarin, bosen-
tan, etanercept) are summarized in Table 1 (closed studies)
and Table 2 (ongoing studies). These studies were cited from
the Thomson Pharma database, as the review of all recently
completed or ongoing clinical trials exceeds the scope of this
review.
Recently, the ATS Guidelines Committee made recom-
mendations of varying strength against the use of most
therapies based on data from the completed studies. Treat-
ment recommendations for speciﬁc therapies are based on
the Grades of Recommendation, Assessment, Development,
and Evaluation (GRADE) approach [147]. For example, the
recommendationagainsttheuseofcorticosteroidmonother-
apy, colchicine, cyclosporine A, combined corticosteroid and
immune-modulator therapy, IFN gamma-1b, bosentan, and
etanercept for the treatment of IPF is strong.
In the absence of longitudinal data, management of
IPF is largely driven by the severity of pulmonary function
impairment.Aperiodofobservationaftersmokingcessation
is usually warranted to allow spontaneous regression of dis-
ease. Relatively good prognosis after smoking cessation with
some additive eﬀects of glucocorticosteroids distinguishes
smoking-related interstitial lung disease from IPF [148].
As described earlier, life-long nonsmokers have a better
outcome than former smokers and the combined group of
current and former smokers in IPF [15]. Interestingly, cur-
rent smokers werefoundto have a much longer survivalthan
former smokers in a recent large study of IPF [16]. It is not
yet clear whether ongoing smoking is genuinely protective
against disease progression. Further studies for the potential
mechanisms by which cigarette smoking may aﬀect patients
withIPFmayprovidebetterinsightintotheeﬀectofsmoking
on the prognosis of IPF.
7. Conclusions
There is a clear need for novel therapies in the treatment
of IPF, as conventional therapy has limited eﬃcacy or
unfavorable safety proﬁle and no FDA-approved therapies
exist. There are a number of ongoing clinical trials tar-
geting ﬁbrogenic, inﬂammatory, and oxidative pathways.
Furthermore, continued eﬀort on better understanding the
mechanisms of disease may provide better treatment options
in the future. One of the key risk factors for development
of IPF, accelerated loss of lung function, and survival is
cigarette smoking. The only therapeutic option for these
patients with IPF is observation for a period of time after
smoking cessation. A search for the potential mechanisms
by which cigarette smoking aﬀects IPF and patients with IPF
may provide insights on a novel therapeutic target against
smoking-induced progression of IPF. A strategy to better
understand the eﬀect of smoking on IPF would be to stratify
patients based on smoking status and compare the treatment
responses between smokers and nonsmokers in the large
clinical trials.
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